An object of the invention is a complex of 7-deacetyl-forskolin (7-DAFSK) and polyvinylpyrrolidone (PVP). Furthermore, the invention relates to a process for preparing such a 7-DAFSK-PVP complex and to a pharmaceutical composition containing such a complex.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data
processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for
development and distribution of implantable/ambulatory
infusion pumps; design, development and implementation of
operating software for accessing and using a computing
network to connect medical devices to data processing
systems and/or clouds; remote monitoring and distant
programming services for medical devices; software as a
service to connect medical devices; platform as a service to
connect medical devices.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data
processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for
development and distribution of implantable/ambulatory
infusion pumps; design, development and implementation of
operating software for accessing and using a computing
network to connect medical devices to data processing
systems and/or clouds; remote monitoring and distant
programming services for medical devices; software as a
service to connect medical devices; platform as a service to
connect medical devices.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data
processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for
development and distribution of implantable/ambulatory
infusion pumps; design, development and implementation of
operating software for accessing and using a computing
network to connect medical devices to data processing
systems and/or clouds; remote monitoring and distant
programming services for medical devices; software as a
service to connect medical devices; platform as a service to
connect medical devices.
The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and γ-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.
9.
NOVEL PROCESS FOR PREPARING WATER SOLUBLE FORSKOLIN
The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and Ɣ-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.
The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analog and a cAMP enhancer before transplantation.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analogue and a cAMP enhancer before transplantation.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 35/02 - Antineoplastic agents specific for leukemia
12.
COMPOSITION FOR USE IN INCREASING ENGRAFTMENT EFFICACY OF HAEMATOPOETIC STEM CELLS AFTER TRANSPLANTATION
The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analogue and a cAMP enhancer before transplantation.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61P 35/02 - Antineoplastic agents specific for leukemia
13.
COMPOSITION FOR THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE
The present invention provides a composition comprising a prostacyclin analogue, derivative or a pharmaceutically acceptable salt thereof, for use in preventing or treating the sinusoidal obstruction syndrome and/or hepatic veno-occlusive disease (VOD) as well as treatment regimens therefor.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.
A method for the preparation of treprostinil and its derivatives is described. In contrast to prior art, this method utilizes an easily scalable enzymatic resolution of a key intermediate for making these compounds. Another significant improvement of the described method over prior methods is the regioselective Claisen rearrangement of a 5-allyloxy-benzaldehyde precursor, which is facilitated by a bromo substituent in 2-position.
C07C 59/115 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
C07C 51/377 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by hydrogenolysis of functional groups
C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
C12P 31/00 - Preparation of compounds containing a five-membered ring having two side-chains in ortho position to each other, and having at least one oxygen atom directly bound to the ring in ortho position to one of the side-chains, one side-chain containing, no
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.
The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.
The present invention provides a composition comprising at least one prostacyclin or prostacyclin analog or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereof; Derivatives thereof
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
20.
Method for enhancing engraftment of haematopoetic stem cells
The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analog to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analog for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Abstract Methods to produce treprostinal and intermediate compounds made in the process are disclosed. The intermediate compounds comprise a compound of formula I or formula II, o-PG2 0 X Ra a X R ¨0 Y.-- OPG1 OPG1 11 wherein, X is Br and Y is H; PG1 is selected from the group consisting of methyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, benzyl, 4-methoxybenzyl, 2,6-dichlorobenzyl, 3,4-dichloro- benzyl; -CH2COOH, -CH2COORx, and -CH2CH2OPG2; PG2 is is tetrahydropyranyl (THP), SiRiR2R3; CH20Rx, or tert- butyldimethylsilyl (TBDMS); R1, R2, and R3 are independently from one another selected from the group consisting of methyl, isopropyl, t-butyl, and phenyl; Ra is hydrogen, hydroxy -000ORx, -0S02Rx, CI, Br F, I, -SR, or -SO2Rx; and Rx is C1_4alkyl or aryl. Date Recue/Date Received 2020-04-28
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
C07C 51/08 - Preparation of carboxylic acids or their salts, halides, or anhydrides from nitriles
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
C07C 45/61 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of C=O groups
C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
23.
PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF
A method for the preparation of treprostinil and its derivatives is described. In contrast to prior art, this method utilizes an easily scalable enzymatic resolution of a key intermediate for making these compounds. Another significant improvement of the described method over prior methods is the regioselective Claisen rearrangement of a 5-allyloxy-benzaldehyde precursor, which is facilitated by a bromo substituent in 2-position.
C07C 67/29 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
C07C 69/18 - Acetic acid esters of trihydroxylic compounds
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
C07C 51/377 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by hydrogenolysis of functional groups
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
24.
NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS
The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
25.
NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS
The present invention provides a composition comprising at least one prostacyclin orprostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one compound selected from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycin or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides a composition comprising Treprostiniland a compound from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycinor a pharmaceutically acceptable salt thereof.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
27.
PROSTACYCLIN ANALOGUE COMPOSITION AND METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS
The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.
The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
C12N 5/078 - Cells from blood or from the immune system
The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61P 11/00 - Drugs for disorders of the respiratory system